Kenvue Inc.KVUE
NYSE•Consumer Defensive•Household & Personal Products
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Kenvue Inc. (KVUE) reported trailing twelve months revenue of $15.29B as of March 2026, a 0.1% decline year-over-year. Quarterly revenue reached $3.91B, reflecting a contraction in sales.
Kenvue Inc. generated $1.62B in TTM net income, with quarterly EBITDA of $910.00M. The operating margin expanded from 14.9% to 19.6%, suggesting improving cost efficiency and pricing discipline.
The spread between operating margin (19.6%) and net margin (12.1%) indicates moderate non-operating costs. Net margin has improved from 8.6% a year ago, signaling stronger bottom-line efficiency.
KVUE trades at a P/E of 21.9x (in line with broad market averages) and a P/S of 2.3x. The price-to-book ratio of 3.3x reflects a moderate premium to book value.
The company generated $350.00M in free cash flow over the trailing twelve months, a 40.6% increase year-over-year, indicating cash generation ability. The balance sheet shows $26.85B in total assets with $7.07B in long-term debt against $10.61B in stockholders equity for a debt-to-equity ratio of 0.7. Data based on the most recent quarterly reports.
Competitive analysis based on 13 quarters of fundamental data
Operating margins are expanding at ~14.7%, suggesting durable pricing power and cost discipline.
ROE is positive at ~12.6% on average, adequate but below the threshold typically associated with wide moats.
Free cash flow is consistently positive and growing — a hallmark of a capital-light business that can self-fund growth.
Revenue has been flat or declining over recent quarters, which may indicate eroding demand or competitive pressure.
Data-driven red flags and warnings across 13 quarters
Margins are stable or improving at ~17.1% — no sign of cost or pricing stress.
FCF covers net income by 1.8x on average — earnings are well-supported by cash generation.
D/E ratio is 0.7 — conservative capital structure with low financial risk.
Revenue has softened, declining in 5 quarters. Monitor for further erosion.
Free cash flow is consistently positive — the business self-funds without external capital reliance.
Share count is stable — no significant dilution or buyback activity.